Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPUGEN LTDCGEN · Entity 6149 | Director | July 29, 2026 | July 30, 2026 |
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director | June 26, 2024 | June 27, 2024 |
| ESSA Pharma Inc.EPIX · Entity 15763 | Director | March 25, 2024 | March 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPUGEN LTD
Report date July 29, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,180 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Grant · Acquired 7,500 · Balance 20,180 F1: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2036-07-29 | Direct | 10,000 |
Reported balance
After 2026-07-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-29 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
F2: This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
Carisma Therapeutics Inc.
Report date June 26, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2034-06-26 | Direct | 19,350 |
Reported balance
After 2024-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-26 · Grant · Acquired 19,350 · Balance 19,350 F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.
ESSA Pharma Inc.
Report date March 25, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.04 · Expires 2034-03-25 | Direct | 50,000 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 50,000 · Balance 50,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 30, 2026 20:02 UTC | COMPUGEN LTD CGEN · Entity 6149 | GrantShare Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001178913-26-003709 · zk2635766.xml · derivative · entry 2 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-07-29 F2 · derivative.exercise_date: This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 29, 2026 Filed Jul 30, 2026 20:02 UTC | COMPUGEN LTD CGEN · Entity 6149 | GrantOrdinary Shares | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003709 · zk2635766.xml · nonDerivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,180 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 16:56 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 19,350 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-24-075721 · tm2418415-4_4seq1.xml · derivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 19,350 shares Expires 2034-06-26 F1 · derivative.exercise_date: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 12:41 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantOptions · Derivative | 50,000 | $0.00 Strike: $9.04 | $0.00 |
DisclosureSEC source: 0000950172-24-000141 · form4.xml · derivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2034-03-25 Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:19 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 38,700 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001104659-23-069502 · tm2318219-6_4seq1.xml · derivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:23 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 184,621 | Not disclosed Strike: $1.46 | Not disclosed |
DisclosureSEC source: 0001104659-23-030747 · tm238905-6_4seq1.xml · derivative · entry 2 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,621 Underlying: Common Stock · 184,621 shares Expires 2031-11-08 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." F3 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vested on November 9, 2022 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:23 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantCommon stock | 413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-030747 · tm238905-6_4seq1.xml · nonDerivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." Read SEC document |
| June 29, 2022 Filed Nov 1, 2022 11:10 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-22-054977 · doc4.xml · derivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2032-06-29 F1 · derivative.exercise_date: 100% of the options vest after 12 months from the date of grant. Read SEC document |
| December 11, 2020 Filed Jan 11, 2021 16:47 UTC | ESSA Pharma Inc. EPIX · Entity 15763 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002957 · doc4.xml · derivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2030-12-11 F1 · derivative.exercise_date: 25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter. Read SEC document |
| December 11, 2020 Filed Jan 26, 2021 19:03 UTC Amendment | ESSA Pharma Inc. EPIX · Entity 15763 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005516 · doc4a.xml · derivative · entry 1 ZWEIFACH SANFORD S · CIK 0001231269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2030-12-11 F1 · derivative.exercise_date: Vesting terms have been amended such that 100% of the options vest after 12 months from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.